DNLI logo

DNLI
Denali Therapeutics Inc

1,946
Mkt Cap
$2.96B
Volume
2.15M
52W High
$23.77
52W Low
$12.58
PE Ratio
-6.46
DNLI Fundamentals
Price
$18.62
Prev Close
$19.39
Open
$19.01
50D MA
$19.92
Beta
1.70
Avg. Volume
1.45M
EPS (Annual)
-$2.97
P/B
3.19
Rev/Employee
$0.00
$2,024.85
Loading...
Loading...
News
all
press releases
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.read more...
Benzinga·10d ago
News Placeholder
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
Key PointsAcquired 254,857 shares of Denali Therapeutics; estimated transaction value $5.07 million (based on quarterly average price...
Nasdaq News: Markets·11d ago
News Placeholder
Denali Therapeutics (DNLI) Expected to Announce Quarterly Earnings on Monday
Denali Therapeutics (NASDAQ:DNLI) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-denali-therapeutics-inc-stock...
MarketBeat·13d ago
News Placeholder
D.A. Davidson & CO. Invests $1.77 Million in Denali Therapeutics Inc. $DNLI
D.A. Davidson & CO. acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The...
MarketBeat·14d ago
News Placeholder
Denali Therapeutics Inc. $DNLI Shares Bought by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA lifted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 166.3% in the 4th quarter, according to its most recent disclosure with the...
MarketBeat·16d ago
News Placeholder
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued...
MarketBeat·17d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.1% - What's Next?
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.1% - Should You Sell...
MarketBeat·17d ago
News Placeholder
B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI
B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 4th quarter, according to its most recent disclosure with the...
MarketBeat·21d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Denali Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat·22d ago
<
1
2
...
>

Latest DNLI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.